Harden, Rockets get 90 in first half, beat Suns 142-116

first_imgPHOENIX, AZ – NOVEMBER 16: James Harden #13 of the Houston Rockets reacts to a three point shot against the Phoenix Suns during the second half of the NBA game at Talking Stick Resort Arena on November 16, 2017 in Phoenix, Arizona. Christian Petersen/Getty Images/AFPPHOENIX, Arizona—James Harden had 23 of his 48 points in the second quarter while the Houston Rockets scored 90 points in the first half en route to a 142-116 win over the Phoenix Suns on Thursday night.Houston dominated with Chris Paul back in the lineup after missing 14 games with a knee injury. The Rockets made 61 percent of their first-half shots to match the second-most points in a first half in NBA history.ADVERTISEMENT LATEST STORIES MOST READ He finished with 20 points and 11 rebounds.Monroe played amid speculation that he could be traded or have his contract bought out.Sports Related Videospowered by AdSparcRead Next Carpio hits red carpet treatment for China Coast Guard PLAY LIST 02:14Carpio hits red carpet treatment for China Coast Guard02:56NCRPO pledges to donate P3.5 million to victims of Taal eruption00:56Heavy rain brings some relief in Australia02:37Calm moments allow Taal folks some respite03:23Negosyo sa Tagaytay City, bagsak sa pag-aalboroto ng Bulkang Taal01:13Christian Standhardinger wins PBA Best Player award Don’t miss out on the latest news and information. Coco’s house rules on ‘Probinsyano’ set Steam emission over Taal’s main crater ‘steady’ for past 24 hours Ryan Anderson added 24 points for the Rockets, who have won seven of eight.The Suns also shot well in the first half, getting 65 points before the break. They got the lead down to 14 with one of Troy Daniels’ six 3-pointers in the second quarter, but the Rockets repeatedly scored with ease at the other end.Daniels tied a Suns franchise record for 3s in a quarter and led Phoenix with 23 points. Devin Booker added 18 points and 10 assists.The Suns have lost seven of eight.As the first half came to a close, a fan yelled at D’Antoni from the stands. “Sit down Mike, you’re up 40!” D’Antoni, a former Suns coach, turned and deadpanned, “It’s 25. You can’t count.”Center Greg Monroe made his Suns debut, starting and playing 26 minutes. Monroe, acquired by Phoenix from Milwaukee with two draft picks for guard Eric Bledsoe on Nov. 7, was dealing with a left calf strain when he arrived.ADVERTISEMENT Wilder calls out Joshua again for big heavyweight fight Jake says relationship with Shaina ‘goes beyond physical attraction’ Kiss-and-tell matinee idol’s conquests: True stories or tall tales? Houston came up 14 points shy of the franchise record for points in a game. The Rockets knocked down 21 of 44 3-point attempts, and Harden made all 18 of his free throws.Harden, the NBA’s leading scorer, had 33 points at halftime. Houston used a 13-1 over the final 3:08 of the first quarter to take control and was never threatened after that, leading 45-23 going into the second.FEATURED STORIESSPORTSRedemption is sweet for Ginebra, Scottie ThompsonSPORTSMayweather beats Pacquiao, Canelo for ‘Fighter of the Decade’SPORTSBack on the thronePaul, who hadn’t played since the season opener, got the start and didn’t miss a beat, scoring 11 points and handing out 10 assists in limited action.Coach Mike D’Antoni said before the game that getting the two stars, Harden and Paul, in sync will “take care of itself over the next week or so.” D’Antoni planned to play Paul for 20 minutes; Paul saw 21 minutes of action and sat out most of the fourth quarter. It’s too early to present Duterte’s ‘legacy’ – Lacson Margot Robbie talks about filming ‘Bombshell’s’ disturbing sexual harassment scene Jo Koy: My brain always wants to think funny Jake says relationship with Shaina ‘goes beyond physical attraction’ OSG plea to revoke ABS-CBN franchise ‘a duplicitous move’ – Lacson View commentslast_img read more

Companies team up for new drug

first_imgTRENTON, N.J. – Merck & Co. and Schering-Plough Corp., partners looking to grab more of the $32 billion global cholesterol-drug market, will jointly develop a new medicine combining their Zetia with rival Pfizer Inc.’s blockbuster Lipitor. The planned drug, meant to reduce bad cholesterol levels in two ways, could hit the market when Lipitor’s patent expires in a few years, Merck and Schering-Plough said Monday. Information on when human testing would begin was not disclosed. News of the deal pushed up Schering-Plough’s shares more than 2 percent, while Whitehouse Station, N.J.-based Merck shares dipped about 1 percent. Merck and Schering-Plough have a seven-year-old joint venture that markets two cholesterol drugs: Schering-Plough’s Zetia and a combo pill launched in mid-2004 called Vytorin. It combines Zetia and Zocor, Merck’s former blockbuster, which lost patent protection in June 2006. Zetia is the only drug on sale that limits absorption of cholesterol in the digestive tract. Zocor, like other drugs in a popular class called statins, limits cholesterol production in the liver. The Merck-Schering-Plough joint venture promotes Vytorin heavily, stressing that it fights cholesterol in two ways. “We anticipate that the Lipitor/Zetia combination may be more effective than Vytorin on cholesterol reduction and could capture an even larger share of the cholesterol-management market than Vytorin,” analyst Joseph Tooley of A.G. Edwards wrote in a research note. Halit Bander, the head of New York-based Pfizer’s Lipitor medical team, said the company can’t speculate on how the new combination would work. Schering-Plough spokeswoman Mary-Fran Faraji said combining Zetia with any statin reduces cholesterol levels about an extra 20 percent, roughly three times as much benefit as just doubling a statin’s dose. “This will present, if it’s approved, an additional option for physicians and patients,” she said. “There are really tremendous unmet needs in cholesterol management.” Heart disease remains the country’s No. 1 killer and many patients are unable to reduce their level of bad cholesterol – and with it cardiac risk – as much as doctors recommend. Meanwhile, new studies reported Monday that a complementary strategy of trying to stave off heart disease by boosting good cholesterol didn’t work well and had safety problems. Lipitor, the world’s top-selling drug, currently is protected by two patents, one facing a legal challenge, according to Pfizer. It is not expected to face generic competition until March 2010 or later. Last year, Lipitor brought Pfizer $12.9 billion in revenues worldwide, more than three times the combined sales for Zetia and Vytorin of $3.86 billion.160Want local news?Sign up for the Localist and stay informed Something went wrong. Please try again.subscribeCongratulations! You’re all set!last_img read more